New York, November 17, 2016 -- Moody's Investors Service, ("Moody's") assigned a Baa3 rating to Abbott Laboratories' proposed senior unsecured note offering. The rating outlook on the new notes is stable. Proceeds will largely be used to help fund the acquisition of St. Jude Medical, Inc. Abbott has not yet received regulatory approvals for the St. Jude deal, including that from the Federal Trade Commission.
Vollständigen Artikel bei Moodys lesen